Cardiac LXR α protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Cardiac LXR α protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization ; volume:7 ; number:9 ; year:2015 ; pages:1229-1243 ; extent:15
EMBO molecular medicine / European Molecular Biology Organization ; 7, Heft 9 (2015), 1229-1243 (gesamt 15)

Urheber
Cannon, Megan V.
Silljé, Herman HW
Sijbesma, Jürgen WA
Vreeswijk‐Baudoin, Inge
Ciapaite, Jolita
van der Sluis, Bart
van Deursen, Jan
Silva, Gustavo JJ
de Windt, Leon J.
Gustafsson, Jan‐Åke
van der Harst, Pim
van Gilst, Wiek H.
de Boer, Rudolf A.

DOI
10.15252/emmm.201404669
URN
urn:nbn:de:101:1-2022120208154856253817
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:39 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Cannon, Megan V.
  • Silljé, Herman HW
  • Sijbesma, Jürgen WA
  • Vreeswijk‐Baudoin, Inge
  • Ciapaite, Jolita
  • van der Sluis, Bart
  • van Deursen, Jan
  • Silva, Gustavo JJ
  • de Windt, Leon J.
  • Gustafsson, Jan‐Åke
  • van der Harst, Pim
  • van Gilst, Wiek H.
  • de Boer, Rudolf A.

Ähnliche Objekte (12)

TNIP3 protects against pathological cardiac hypertrophy by stabilizing STAT1

TNIP3 protects against pathological cardiac hypertrophy by stabilizing STAT1

HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB‐C/EBP β Axis

HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB‐C/EBP β Axis

CYP2J2 Overexpression Protects against Arrhythmia Susceptibility in Cardiac Hypertrophy

CYP2J2 Overexpression Protects against Arrhythmia Susceptibility in Cardiac Hypertrophy

ANGPTL8 is a negative regulator in pathological cardiac hypertrophy

ANGPTL8 is a negative regulator in pathological cardiac hypertrophy

Oridonin protects against cardiac hypertrophy by promoting P21-related autophagy

Oridonin protects against cardiac hypertrophy by promoting P21-related autophagy

SUMOylation of TEAD1 Modulates the Mechanism of Pathological Cardiac Hypertrophy

SUMOylation of TEAD1 Modulates the Mechanism of Pathological Cardiac Hypertrophy

E3 ubiquitin ligase RNF5 attenuates pathological cardiac hypertrophy through STING

E3 ubiquitin ligase RNF5 attenuates pathological cardiac hypertrophy through STING

Cardiac hypertrophy at autopsy

Cardiac hypertrophy at autopsy

Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease

Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

Olive oil protects against cardiac hypertrophy in D-galactose induced aging rats

Olive oil protects against cardiac hypertrophy in D-galactose induced aging rats

Improved cardiac glucose uptake : a potential mechanism for estrogens to prevent the development of cardiac hypertrophy

Hochschulschrift

Improved cardiac glucose uptake : a potential mechanism for estrogens to prevent the development of cardiac hypertrophy

Verbundene Objekte